Compare
Embecta Corp. vs Tandem Diabetes Care Inc vs Inspire Medical Systems, Inc. vs Haemonetics Corp
| Latest fiscal year | Embecta Corp. EMBC | Tandem Diabetes Care Inc TNDM | Inspire Medical Systems, Inc. INSP | Haemonetics Corp HAE |
|---|---|---|---|---|
| Year ended | 2025-09-30 | 2025-12-31 | 2025-12-31 | 2026-03-28 |
| Revenue | $1.08B | $1.01B | $911.98M | $1.33B |
| Revenue growth (YoY) | -3.8% | +7.9% | +13.6% | -2.0% |
| Gross margin | 62.6% | 53.8% | 85.4% | 59.0% |
| Operating margin | 22.4% | -18.5% | 5.6% | 11.7% |
| Net margin | 8.8% | -20.2% | 15.9% | 7.3% |
| Net income | $95.40M | -$204.71M | $145.42M | $97.31M |
| EPS (Diluted) | $1.62 | -$3.04 | $4.89 | $2.05 |
| Operating cash flow | $191.70M | -$9.72M | $116.98M | $293.22M |
| Free cash flow | $182.40M | -$29.67M | $78.48M | $260.44M |
| Cash & equivalents | $225.50M | $90.63M | $104.81M | $245.44M |
| Total assets | $1.09B | $881.11M | $907.32M | $2.40B |
| Total liabilities | n/a | $725.94M | $126.16M | n/a |
| Shareholders' equity | -$650.60M | $155.17M | $781.16M | $796.32M |
| Return on year-end equity | n/a | -131.9% | 18.6% | 12.2% |
| Shares outstanding | 58.50M | 68.29M | 28.58M | 45.25M |
Revenue, most recent five fiscal years
| Fiscal year | Embecta Corp. | Tandem Diabetes Care Inc | Inspire Medical Systems, Inc. | Haemonetics Corp |
|---|---|---|---|---|
| Latest | $1.08B Ended 2025-09-30 | $1.01B Ended 2025-12-31 | $911.98M Ended 2025-12-31 | $1.33B Ended 2026-03-28 |
| 1 year earlier | $1.12B Ended 2024-09-30 | $940.20M Ended 2024-12-31 | $802.80M Ended 2024-12-31 | $1.36B Ended 2025-03-29 |
| 2 years earlier | $1.12B Ended 2023-09-30 | $747.72M Ended 2023-12-31 | $624.80M Ended 2023-12-31 | $1.31B Ended 2024-03-30 |
| 3 years earlier | $1.13B Ended 2022-09-30 | $801.22M Ended 2022-12-31 | $407.86M Ended 2022-12-31 | $1.17B Ended 2023-04-01 |
| 4 years earlier | $1.17B Ended 2021-09-30 | $702.80M Ended 2021-12-31 | $233.39M Ended 2021-12-31 | $993.20M Ended 2022-04-02 |